Collegium Q3 revenue $136.7M (+8% YoY), adj. EBITDA record $89.4M, guidance tightened

COLLEGIUM PHARMACEUTICAL, INC

2023-Q3 EPS reported $0.46 revenue$417,022,000

GAAP net income $20.6M vs $0.5M; diluted EPS $0.53; adjusted EPS $1.34.
Belbuca net revenue $45.4M (+17% YoY); Xtampza ER $39.8M; Nucynta franchise $47.5M.
Updated FY23 guidance: revenue $565-570M, adj. EBITDA $360-365M, op. expenses $125-130M.
Nucynta exclusivity extended to July 2026; board authorized $25M ASR program.
Cash and securities $304.6M, up from $173.7M at Dec 31, 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended September 30, 2023 results: revenue $136.7 million, net income $20.6 million, EPS $0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted). Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: $136.7 million
Net income: $20.6 million
EPS: $0.61 GAAP earnings per share (basic) and $0.53 GAAP earnings per share (diluted)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

not filed, under Item 2.02 of this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports Third Quarter 2023 Financial Results – Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19%

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-017980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.